Anales de la RANM

48 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS José María Fernández-Rañada An RANM · Año 2019 · número 136 (01) · páginas 43 a 48 14. Stilgenbauer S, Eichhorst B, Schetelig J et al. Ve- netoclax in relapsed or refractory chronic lym- phocytic leukaemia with 17p deletion: a multi- centre, open-label, phase 2 study. Lancet Oncol 2016; 17: 768-778. 15. Passweg JR, Baldomero H, Bader P et al. Is the use of unrelated donor transplantation leveling off in Europe?: The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl 2018 53(9): 1139- 1148. 16. Castagna L, Devillier R, Vey N, Blaise D. T-cell- replete haploidetical transplantation in acute myeloid leukemia. Exp Hematol 2018; 58: 5-16. 17. Santoro N, Labopin M, Giannotti F et al. Un- manipulated haploidentical in comparison with matched unrelated donor stem cell transplanta- tion in patients 60 years and older with acute myeloid leukemia: a comparative study on be- half of the ALWP of the EBMT. J Hematol Oncol 2018 16; 11(1): 55. 18. Lee CJ, Savani N, Mohty M et al. Haploidentical Hematopoietic Cell Transplantation For Adult Acute Myeloid Leukemia: A Position Statement From The Acute Leukemia Working Party Of The European Society For Blood And Marrow Transplantation. Haematologica 2017; 102(11): 1810-1822. 19. Canaani J, Labopin M, Huang XJ et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol 2018 ; 93(6): 736-744. 20. Mufflly L, Pasquini MC, Martens M et al. Incre- asing use of allogeneic hematopoietic cell trans- plantation in patients aged 70 years and older in the United States. Blood 2017 31; l30(9): 1156- 1164. 21. Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL. Al- logeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Can- cers (Basel) 2018 , 10(6): 179. 22. Zuckerman T. Allogeneic transplant: does age still matter? Blood 2017; l30(9): 1079-1080. 23. Cohen BC. Novel therapies for relapsed/refrac- tory aggressive lymphomas. Hematology Am Soc Hematol Educ Program 2018 ; 2018(1): 75- 82. 24. Locke FL, Neelapu SS, Bartlett NL et al. Phase 1 Results of ZUMA-1: a multicenter study of KTE- C19 Anti-CD19 CAR T Cell Therapy in Refrac- tory Aggressive Lymphoma. Mol Ther 2017 4;25(1):285-295. 25. Neelapu SS, Locke FL, Bartlett NL et al. Axi- cabtagene Ciloleucel CAR T-Cell Therapy in Re- fractory Large B-Cell Lymphoma. N Engl J Med 2017 28; 377(26): 2531-2544. 26. Schuster SJ, Bishop MR, Tam CS et al. Tisagenle- cleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45-56. 27. Lulla PD, Hill LC, Ramos CA, Heslop HE. The Use of Chimeric Antigen Receptor T Cells in Pa- tients With Non-Hodgkin Lymphoma. Clin Adv in Hematol Oncol 2018 ; 16(5): 375-386. Si desea citar nuestro artículo: Fernández-Rañada J.M. Trasplante de progenitores hematopoyéticos ANALES RANM [Internet].Real Academia Nacional de Medicina de España; An RANM · Año 2019 · número 136 (01) · páginas 43– 48 DOI: 10.32440/ar.2019.136.01. rev08 DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en la presente revisión.